These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36909105)

  • 1. Determination of Factors Influencing the Health Belief Model (HBM) and Adherence to Intravitreal Anti-vascular Endothelial Growth Factor (VEGF) Among Patients With Diabetic Macular Edema (DME).
    Ting Yih Ling J; Mohd Zain A; Naffi AA; Mustapha M; Wan Abdul Halim WH
    Cureus; 2023 Feb; 15(2):e34669. PubMed ID: 36909105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs in Diabetic Macular Edema in an Egyptian Population: A Health Belief Model.
    Habib AE; Abdel-Kader AA; Eissa IM; Awadein A
    Curr Eye Res; 2019 Mar; 44(3):303-310. PubMed ID: 30383436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 4. The psychological status of patients with delayed intravitreal injection for treatment of diabetic macular edema due to the COVID-19 pandemic.
    Zaini MA; Mohd Zain A; Din NM; Mustapha M; Sidi H
    PLoS One; 2023; 18(8):e0290260. PubMed ID: 37624864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of micropulse laser combined with ranibizumab in diabetic macular edema treatment: study protocol for a randomized controlled trial.
    Mi X; Gu X; Yu X
    Trials; 2022 Sep; 23(1):736. PubMed ID: 36056443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Visual Consequences of Non-adherent Patients Receiving Anti-vascular Endothelial Growth Factor (VEGF) Injections at King Fahad Specialist Hospital (KFSH), Qassim Region.
    Alharbi AD; Alotayk NI; Alaboudi AA; Alammar AY; Aldekhail MI; Alharbi MA; Alsamel TA; Aljutayli MA; Aljarbou AM; Aljameeli OM
    Cureus; 2023 Aug; 15(8):e44340. PubMed ID: 37779785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis.
    Wang X; He X; Qi F; Liu J; Wu J
    Front Pharmacol; 2022; 13():876386. PubMed ID: 35814207
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice.
    Maloney MH; Schilz SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
    Ophthalmology; 2019 Jul; 126(7):1007-1015. PubMed ID: 30292542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Clinical Practice of Single Center: Three-Year Outcomes.
    Choovuthayakorn J; Phinyo P; Tantraworasin A; Kunavisarut P; Patikulsila D; Chaikitmongkol V; Watanachai N; Pathanapitoon K
    Ophthalmic Res; 2021; 64(3):483-493. PubMed ID: 33053556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT.
    Müller S; Junker S; Wilke T; Lommatzsch A; Schuster AK; Kaymak H; Ehlken C; Ziemssen F
    Int J Retina Vitreous; 2021 Jun; 7(1):43. PubMed ID: 34078475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual outcomes of observation, macular laser and anti-VEGF in diabetic macular edema in type 1 diabetes: a real-world study.
    Wirkkala J; Kubin AM; Ohtonen P; Yliselä J; Siik T; Hautala N
    BMC Ophthalmol; 2022 Jun; 22(1):258. PubMed ID: 35681133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare Utilization and Treatment Patterns in Diabetic Macular Edema in Korea: a Retrospective Chart Review.
    Park KH; Kim YY; Jo YJ; Oh J; Lee JE; Lee JE; Park DH; Kang SW; Lee WK; Kim HK; Adena M; Tan J; Kim SD
    J Korean Med Sci; 2019 Apr; 34(15):e118. PubMed ID: 31001935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Patients With Active Diabetic Macular Edema at the Time of Cataract Surgery Managed With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Starr MR; Mahr MA; Smith WM; Iezzi R; Barkmeier AJ; Bakri SJ
    Am J Ophthalmol; 2021 Sep; 229():194-199. PubMed ID: 33852907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
    Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
    Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrophy of the central neuroretina in patients treated for diabetic macular edema.
    Karst SG; Schuster M; Mitsch C; Meyer EL; Kundi M; Scholda C; Schmidt-Erfurth UM
    Acta Ophthalmol; 2019 Dec; 97(8):e1054-e1061. PubMed ID: 31228332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy.
    Wilkins CS; Sobol EK; Lema GM; Lee JG; Rosen RB; Deobhakta A
    Eur J Ophthalmol; 2022 Sep; 32(5):NP37-NP41. PubMed ID: 33757333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
    Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan.
    Kitano S; Sakamoto T; Goto R; Fukushima A; Vataire AL; Hikichi Y
    J Med Econ; 2019 Mar; 22(3):254-265. PubMed ID: 30550375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.